Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Corporate Dr., 2 Nd Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 502 % +35.3%
Debt-to-equity 77.1 % +63.8%
Return On Equity -114 % -9.58%
Return On Assets -64.6 % +8.99%
Operating Margin -2.57K %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 3.32M shares -92.4%
Entity Public Float 20.2M USD -42.6%
Common Stock, Value, Issued 8K USD +100%
Weighted Average Number of Shares Outstanding, Basic 6.27M shares +261%
Weighted Average Number of Shares Outstanding, Diluted 6.27M shares +261%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.68M USD +15.2%
Research and Development Expense 76.5M USD +9.46%
General and Administrative Expense 24.1M USD -23.1%
Operating Income (Loss) -94.6M USD -11.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -76.7M USD +5.1%
Income Tax Expense (Benefit) 274K USD -68.7%
Net Income (Loss) Attributable to Parent -77M USD +5.78%
Earnings Per Share, Basic 6.71 USD/shares +70.4%
Earnings Per Share, Diluted 6.71 USD/shares +70.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.3M USD -49.8%
Cash, Cash Equivalents, and Short-term Investments 74.9M USD +6.39%
Other Assets, Current 4.79M USD +15.7%
Assets, Current 79.8M USD +6.94%
Property, Plant and Equipment, Net 2.58M USD -29.4%
Operating Lease, Right-of-Use Asset 5.39M USD -22.3%
Other Assets, Noncurrent 635K USD +1.93%
Assets 88.4M USD +3%
Accounts Payable, Current 2.74M USD -6.83%
Employee-related Liabilities, Current 4.41M USD +7.94%
Accrued Liabilities, Current 14.2M USD +14.9%
Liabilities, Current 21M USD -6.73%
Operating Lease, Liability, Noncurrent 5.55M USD -33.4%
Other Liabilities, Noncurrent 133K USD -50.2%
Liabilities 38.3M USD +23.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 577K USD +16.1%
Retained Earnings (Accumulated Deficit) -536M USD -16.8%
Stockholders' Equity Attributable to Parent 50.1M USD -8.62%
Liabilities and Equity 88.4M USD +3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.7M USD -1.6%
Net Cash Provided by (Used in) Financing Activities -19K USD -1800%
Net Cash Provided by (Used in) Investing Activities -88.6M USD -543%
Common Stock, Shares Authorized 20.8M shares -93.5%
Common Stock, Shares, Issued 3.32M shares -92.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.4M USD -49.7%
Deferred Tax Assets, Valuation Allowance 34.2M USD -68.8%
Deferred Tax Assets, Gross 36.6M USD -67.5%
Operating Lease, Liability 10.9M USD -10.9%
Depreciation 1.29M USD -23.6%
Payments to Acquire Property, Plant, and Equipment 7K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -76.9M USD +5.49%
Lessee, Operating Lease, Liability, to be Paid 12.6M USD -14.8%
Property, Plant and Equipment, Gross 14.1M USD -1.82%
Operating Lease, Liability, Current 3.39M USD +5.94%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.68M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD +4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -11.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.75M USD -33.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.8M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 99K USD -96.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.44M USD -59.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.38M USD -25%
Share-based Payment Arrangement, Expense 2.04M USD -36.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%